Search results for "Overall"

showing 10 items of 145 documents

Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of …

2016

The recent advances in identification of the molecular mechanisms related to tumorigenesis and angiogenesis, along with the understanding of molecular alterations involved in renal cell carcinoma (RCC) pathogenesis, has allowed the development of several new drugs which have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). This process has resulted in clinically significant improvements in median overall survival and an increasing number of patients undergoes two or even three lines of therapy. Therefore, it is necessary a long-term perspective of the treatment: planning a sequential and personalized therapeutic strategy to improve clinical outcome, the potential to a…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practicemedicine.drug_classSettore MED/06 - Oncologia MedicaVEGF receptorsAntineoplastic AgentsReviewurologic and male genital diseasesrenal cell cancerTyrosine-kinase inhibitor03 medical and health sciencesangiogenesis0302 clinical medicinetyrosine kinase inhibitorQuality of lifeRenal cell carcinomaInternal medicineAngiogenesis; MTOR; Renal cell cancer; Tyrosine kinase inhibitor; VEGFr; OncologymedicineOverall survivalAnimalsHumansMolecular Targeted TherapyPrecision MedicineCarcinoma Renal CellTherapeutic strategybiologybusiness.industryPrecision medicinemedicine.diseaseKidney NeoplasmsSurgeryAngiogenesiSettore MED/18 - Chirurgia GeneraleVEGFr030104 developmental biologyOncology030220 oncology & carcinogenesisbiology.proteinmTORbusiness
researchProduct

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer

2018

Giuseppe Cicero,1 Rossella De Luca,1 Francesco Dieli2 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, Palermo, Italy Background: In many clinical trials designed to assess the efficacy of anticancer treatments, overall survival (OS) is often used as a primary endpoint despite its several points of weakness. Methods: This study evaluated the role of progression-free survival (PFS) in the first three lines of treatment as a potential surrogate endpoint of OS in patients with metastatic colorectal cancer (MCRC). One hu…

0301 basic medicineOncologymedicine.medical_specialtycolorectal neoplasm overall survival progression-free survival surrogate endpoint liver metastates avastin egorafenibColorectal canceroverall survivalegorafenibOncoTargets and Therapy03 medical and health sciences0302 clinical medicineInternal medicinesurrogate endpoint liver metastatesOverall survivalClinical endpointMedicinePharmacology (medical)In patientProgression-free survivalavastinOriginal Researchbusiness.industryTime to progressionSurrogate endpointmedicine.diseaseClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesiscolorectal neoplasmbusinessprogression-free survivalOncoTargets and Therapy
researchProduct

Bolton ratios in Portuguese subjects among different malocclusion groups

2018

Background Several methods have been described to estimate inter-arch tooth size relationship, such as Bolton's ratios. The aims of this study were to verify the validity of Bolton indexes in a sample of untreated Portuguese subjects based on Angle classification and to evaluate the gender difference. Material and Methods 168 pre-treatment dental casts of orthodontics Portuguese subjects (59 males and 109 females) with different occlusions were used, which were selected randomly from 541 consecutively treated orthodontic patients. The mesiodistal widths from first molar to first molar were measured on each pre-treatment cast to the nearest 0.01 mm using digital caliper, and Bolton's anterio…

0301 basic medicineOrthodonticsClass iiiMandibular first molarStandard deviationNormal occlusion03 medical and health sciencesPortuguese population0302 clinical medicineOcclusionmedicineGeneral DentistryMathematicsOrthodonticsBolton anterior and overall ratiosResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaselanguage.human_language030104 developmental biologyUNESCO::CIENCIAS MÉDICASlanguageCalipersPortuguese populationMalocclusionPortugueseMalocclusionJournal of Clinical and Experimental Dentistry
researchProduct

Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small ce…

2019

Background: Lung cancer is the leading cause of cancer-related death worldwide, with 5-year overall survival less than 15%. Therefore, it is essential to find biomarkers for early detection and prognosis. Aberrant DNA methylation is a common feature of human cancers and its utility is already recognized in cancer management. The aim of this study was to explore the diagnostic and prognostic value of the promoter methylation status of the ASC/TMS1/PYCARD and MyD88 genes, key adaptor molecules in the activation of the innate immune response and apoptosis pathways. Methods: A total of 50 non-small cell lung cancer (NSCLC) patients were enrolled in the study. Methylation of bisulphite converted…

0301 basic medicinebusiness.industrynon-small cell lung cancer (NSCLC)Basic Medical SciencesPromoterPYCARDMethylationmedicine.disease3. Good health03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCpG site030220 oncology & carcinogenesismedicineCancer researchASC/TMS1/PYCARD ; MyD88 ; methylation status ; association ; overall survival ; TNM ; non-small cell lung cancer (NSCLC)Stage (cooking)Lung cancerbusinessGene
researchProduct

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-pe…

2018

// Pierpaolo Correale 1 , Cirino Botta 2 , Nicoletta Staropoli 3 , Valerio Nardone 4 , Pierpaolo Pastina 4 , Cristina Ulivieri 5 , Claudia Gandolfo 6 , Tatiana Cosima Baldari 5 , Stefano Lazzi 7 , Domenico Ciliberto 3 , Rocco Giannicola 1 , Antonella Fioravanti 8 , Antonio Giordano 9 , Silvia Zappavigna 10 , Michele Caraglia 9, 10 , Pierfrancesco Tassone 2, 3, 10 , Luigi Pirtoli 4 , Maria Grazia Cusi 6 and Pierosandro Tagliaferri 3 1 Unit of Medical Oncology, Grand Metropolitan Hospital Bianchi Melacrino Morelli, Reggio-Calabria, Italy 2 Medical Oncology Unit, AUO Mater Domini, Magna Graecia University, Catanzaro, Italy 3 Department of Experimental and Clinical Medicine, Magna Graecia Unive…

0301 basic medicinemedicine.medical_specialtyColorectal cancerThymidylate synthaseK-ra03 medical and health sciences0302 clinical medicineInternal medicineOverall survivalCancer vaccineMedicineIn patientK-rasAntitumor activitybiologybusiness.industryBio-markerUniversity hospitalmedicine.diseasePredictive valueColorectal cancerClinical trial030104 developmental biologyBio-markers; Cancer vaccine; Colorectal cancer; K-ras; Thymidylate synthase; OncologyOncology030220 oncology & carcinogenesisbiology.proteinThymidylate synthaseBio-markersbusinessResearch Paper
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

2021

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan&ndash

0301 basic medicinemedicine.medical_specialtyPrognostic factorobesityrenal cell carcinomaMultivariate analysisCabozantinibPrognosiClinical Biochemistrybody mass indexurologic and male genital diseasesGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRenal cell carcinomacabozantinibInternal medicinemedicineOverall survivalIn patientneoplasmsPathologicallcsh:R5-920real-world databusiness.industrybody mass index; cabozantinib; obesity; prognosis; real-world data; renal cell carcinoma; targeted therapymedicine.diseasetargeted therapyfemale genital diseases and pregnancy complications030104 developmental biologychemistry030220 oncology & carcinogenesisprognosislcsh:Medicine (General)businessBody mass indexDiagnostics
researchProduct

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes.

2016

Background: The identification of biomarkers for the estimation of cancer patients’ survival is a crucial problem in modern oncology. Recently, the Affymetrix DMET (Drug Metabolizing Enzymes and Transporters) microarray platform has offered the possibility to determine the ADME (absorption, distribution, metabolism, and excretion) gene variants of a patient and to correlate them with drug-dependent adverse events. Therefore, the analysis of survival distribution of patients starting from their profile obtained using DMET data may reveal important information to clinicians about possible correlations among drug response, survival rate, and gene variants. Methods: In order to provide support …

0301 basic medicinepharmacogenomicoverall survivalBiomedical EngineeringDME genes; genotyping microarrays; overall survival; pharmacogenomics; progression-free survivalBioengineeringBiologyBioinformaticsBiochemistryArticlelcsh:Biochemistrygenotyping microarray03 medical and health sciencesmedicineOverall survivallcsh:QD415-436Progression-free survivalgenotyping microarraysAdverse effectSurvival rateGeneADMEpharmacogenomicsADME geneCancermedicine.diseaseADME genesgenotyping microarrays; ADME genes; pharmacogenomics; overall survival; progression-free survival030104 developmental biologyPharmacogenomicsprogression-free survivalBiotechnologyMicroarrays (Basel, Switzerland)
researchProduct

2019

Foam rolling is thought to improve muscular performance and flexibility as well as to alleviate muscle fatigue and soreness. For this reason, foam rolling has become a popular intervention in all kinds of sport settings used to increase the efficiency of training or competition preparation as well as to speed post-exercise recovery. The objective of this meta-analysis was to compare the effects of foam rolling applied before (pre-rolling as a warm-up activity) and after (post-rolling as a recovery strategy) exercise on sprint, jump, and strength performance as well as on flexibility and muscle pain outcomes and to identify whether self-massage with a foam roller or a roller massager is more…

030222 orthopedicsmedicine.medical_specialtyFlexibility (anatomy)Muscle fatiguePhysiology030229 sport sciencesPain sensation03 medical and health sciences0302 clinical medicinemedicine.anatomical_structurePhysical medicine and rehabilitationSprintPhysiology (medical)Meta-analysismedicineJumpFoam rollingOverall performanceMathematicsFrontiers in Physiology
researchProduct

Evaluation of the antibacterial power and biocompatibility of zinc oxide nanorods decorated graphene nanoplatelets: New perspectives for antibiodeter…

2017

Background Nanotechnologies are currently revolutionizing the world around us, improving the quality of our lives thanks to a multitude of applications in several areas including the environmental preservation, with the biodeterioration phenomenon representing one of the major concerns. Results In this study, an innovative nanomaterial consisting of graphene nanoplatelets decorated by zinc oxide nanorods (ZNGs) was tested for the ability to inhibit two different pathogens belonging to bacterial genera frequently associated with nosocomial infections as well as biodeterioration phenomenon: the Gram-positive Staphylococcus aureus and the Gram-negative Pseudomonas aeruginosa. A time- and dose-…

3003Staphylococcus aureuslcsh:Medical technologyBiocompatibilitylcsh:Biotechnologyharmful to the environmentBiomedical EngineeringPharmaceutical ScienceMedicine (miscellaneous)Overall; ZNGs represent a promising candidate for developing biocompatible materials that can be exploitable in antimicrobial applications without releasing toxic compounds; harmful to the environment; Bioengineering; Medicine (miscellaneous); Molecular Medicine; Biomedical Engineering; Applied Microbiology and Biotechnology; 3003Biocompatible MaterialsBioengineeringNanotechnology02 engineering and technology010402 general chemistry01 natural sciencesApplied Microbiology and BiotechnologyNanomaterialsExtracellular polymeric substancelcsh:TP248.13-248.65HumansZNGs represent a promising candidate for developing biocompatible materials that can be exploitable in antimicrobial applications without releasing toxic compoundNanotubesbiologyChemistryResearchBiofilm021001 nanoscience & nanotechnologybiology.organism_classificationAntimicrobialAnti-Bacterial Agents0104 chemical scienceslcsh:R855-855.5NanotoxicologyBiofilmsPseudomonas aeruginosaZNGs; biodeterioration; antimicrobial nanomaterialMolecular MedicineGraphiteNanorodOverallZinc Oxide0210 nano-technologyBacteria
researchProduct